Marina Grandis

List of Publications by Year
in descending order

83	2,270	257450 24	233421 45
papers	citations	h-index	g-index

84	84	84	2603
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	3.6	13
2	Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT. Neurological Sciences, 2022, 43, 2759-2764.	1.9	2
3	An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic <scp>hyperCKemia</scp>. Muscle and Nerve, 2022, 65, 96-104.	2.2	10
4	Genetic Workup for Charcotâ€“Marieâ€“Tooth Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. Life, 2022, 12, 402.	2.4	4
5	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	3.3	13
6	A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors. Neurological Sciences, 2022, 43, 4567-4570.	1.9	5
7	Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. Neurological Sciences, 2021, 42, 1405-1409.	1.9	7
8	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	3.6	38
9	High-dose immunoglobulin pulse therapy and risk of Covid19 infection. Journal of Neurology, 2021, 268, 1573-1575.	3.6	7
10	Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy. Neuromuscular Disorders, 2021, 31, 134-138.	0.6	1
11	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
12	RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain, 2021, 144, 1542-1550.	7.6	63
13	6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen. Journal of the Neurological Sciences, 2021, 429, 119385.	0.6	0
14	Techniques for the standard histological and ultrastructural assessment of nerve biopsies. Journal of the Peripheral Nervous System, 2021, 26, S3-S10.	3.1	3
15	An eleven-year history of Vanishing White Matter Disease in an adult patient with no cognitive decline and EIF2B5 mutations. A case report. Neurocase, 2021, 27, 452-456.	0.6	2
16	Parsonageâ€“Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine:Âa case report and review of theÂliterature. Journal of Medical Case Reports, 2021, 15, 589.	0.8	22
17	How to define and enhance diagnostic and assistance pathways in neuromuscular diseases during the COVID-19 pandemic: the concept of network.. Acta Myologica, 2021, 40, 172-176.	1.5	0
18	Treadmill training in patients affected by Charcotâ€“Marieâ€“Tooth neuropathy: results of a multicenter, prospective, randomized, singleâ€blind, controlled study. European Journal of Neurology, 2020, 27, 280-287.	3.3	19

#	Article	IF	Citations
19	High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. Pain Medicine, 2020, 21, 576-585.	1.9	11
20	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
21	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15
22	People with Charcot-Marie-Tooth disease and COVID-19: Impaired physical conditions due to the lockdown. An International cross-sectional survey. Annals of Physical and Rehabilitation Medicine, 2020, 63, 557-559.	2.3	5
23	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
24	The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment. International Journal of Rehabilitation Research, 2020, 43, 285-286.	1.3	17
25	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	2.3	24
26	Pregnancy in Charcot-Marie-Tooth disease. Neurology, 2020, 95, e3180-e3189.	1.1	11
27	Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1166-1174.	1.9	99
28	Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question!. Orphanet Journal of Rare Diseases, 2020, 15, 216.	2.7	2
29	Validation of a new hand function outcome measure in individuals with Charcotâ€Marieâ€Tooth disease. Journal of the Peripheral Nervous System, 2020, 25, 413-422.	3.1	3
30	Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3454.	2.4	10
31	Response to Dr. Wee. Pain Medicine, 2020, 21, 2604-2604.	1.9	0
32	Early onset demyelinating Charcotâ€Marieâ€Tooth disease caused by a novel inâ€frame isoleucine deletion in peripheral myelin protein 2. Journal of the Peripheral Nervous System, 2020, 25, 102-106.	3.1	6
33	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica, 2020, 39, 57-66.	1.5	24
34	Comparison of Strength and Dexterity in Professional and Student Violinists: Setting Foundations to Guide Rehabilitation. Medical Problems of Performing Artists, 2020, 35, 130-137.	0.4	1
35	Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype. Journal of Neurology, 2019, 266, 2629-2645.	3.6	23
36	Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11â€¯years. Journal of Neuroimmunology, 2019, 337, 577081.	2.3	3

#	Article	IF	Citations
37	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
38	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
39	A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy. Journal of the Neurological Sciences, 2019, 398, 75-78.	0.6	10
40	Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017. Frontiers in Neurology, 2019, 10, 1218.	2.4	12
41	Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. Journal of Cardiovascular Translational Research, 2019, 12, 514-516.	2.4	3
42	Feasibility of imaging phenotyping (radiomics) on nuclear MRI of major lower limb nerves. Journal of Radiological Review, 2019, 6, .	0.1	1
43	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2019, 19, 187-192.	1.2	1
44	Intravenous versus subcutaneous immunoglobulin â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	10.2	0
45	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193
46	Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy â€œin disguiseâ€. Orphanet Journal of Rare Diseases, 2018, 13, 177.	2.7	2
47	Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis. Journal of		

#	Article	IF	Citations
55	Sural nerve biopsy and functional studies support the pathogenic role of a novel <scp>MPZ</scp> mutation. Neuropathology, 2015, 35, 254-259.	1.2	4
56	Glycans of myelin proteins. Journal of Neuroscience Research, 2015, 93, 1-18.	2.9	12
57	Contribution of copy number variations in <scp>CMT</scp>1X: a retrospective study. European Journal of Neurology, 2015, 22, 406-409.	3.3	3
58	Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 1969-1973.	3.3	9
59	Influence of comorbidities on the phenotype of patients affected by Charcotâ€“Marieâ€“Tooth neuropathy type 1A. Neuromuscular Disorders, 2013, 23, 902-906.	0.6	15
60	Gain of glycosylation: A new pathomechanism of myelin protein zero mutations. Annals of Neurology, 2012, 71, 427-431.	5.3	20
61	Outcome Measures and Rehabilitation Treatment in Patients Affected by Charcot-Marie-Tooth Neuropathy. American Journal of Physical Medicine and Rehabilitation, 2011, 90, 628-637.	1.4	34
62	HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients. Journal of the Peripheral Nervous System, 2011, 16, 287-294.	3.1	57
63	A novel mutation in KIF5A gene causing hereditary spastic paraplegia with axonal neuropathy. Neurological Sciences, 2011, 32, 665-668.	1.9	21
64	Inherited Neuropathies. Current Treatment Options in Neurology, 2011, 13, 160-179.	1.8	44
65	Severe Neuropathy After Diphtheria-Tetanus-Pertussis Vaccination in a Child Carrying a Novel Frame-Shift Mutation in the Small Heat-Shock Protein 27 Gene. Journal of Child Neurology, 2010, 25, 107-109.	1.4	32
66	The spectrum of GNE mutations: allelic heterogeneity for a common phenotype. Neurological Sciences, 2010, 31, 377-380.	1.9	17
67	Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. European Journal of Human Genetics, 2009, 17, 1129-1134.	2.8	35
68	Impaired Expression of Ciliary Neurotrophic Factor in Charcot-Marie-Tooth Type 1A Neuropathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 441-455.	1.7	17
69	Gap junction beta 1 (GJB1) gene mutations in Italian patients with X-linked Charcot-Marie-Tooth disease. Journal of Human Genetics, 2008, 53, 529-533.	2.3	13
70	Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Human Molecular Genetics, 2008, 17, 1877-1889.	2.9	69
71	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Antiâ€“Myelin-Associated Glycoprotein Polyneuropathy. Archives of Neurology, 2007, 64, 1531.	4.5	30
72	Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System, 2007, 12, 102-107.	3.1	98

#	Article	IF	Citations
73	Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. Journal of Comparative Neurology, 2006, 498, 252-265.	1.6	49
74	Current therapy for Charcot-Marie-Tooth disease. Current Treatment Options in Neurology, 2005, 7, 23-31.	1.8	24
75	Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain, 2005, 128, 1168-1177.	7.6	113
76	Phenotypic clustering in MPZ mutations. Brain, 2004, 127, 371-384.	7.6	257
77	Mycophenolate mofetil in dysimmune neuropathies: A preliminary study. Muscle and Nerve, 2004, 29, 748-749.	2.2	51
78	Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Experimental Neurology, 2004, 190, 213-223.	4.1	18
79	Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. Neurobiology of Disease, 2004, 16, 263-273.	4.4	34
80	The D355V Mutation Decreases EGR2 Binding to an Element within the Cx32 Promoter. Neurobiology of Disease, 2001, 8, 700-706.	4.4	27
81	Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. Muscle and Nerve, 2001, 24, 622-629.	2.2	21
82	PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. Annals of Neurology, 2001, 50, 47-55.	5.3	23
83	Very High Prevalence of Right-to-Left Shunt on Transcranial Doppler in an Italian Family with Cerebral Autosomal Dominant Angiopathy with Subcortical Infarcts and Leukoencephalopathy. European Neurology, 2001, 46, 198-201.	1.4	32